Combined Analysis of Mifepristone for Psychotic Depression; Plasma Levels Associated with Clinical Response

We present a combined analysis of all controlled Phase 2/3 studies to report antipsychotic differences between treatment with mifepristone or placebo and to evaluate the relative contributions to response of attaining an a priori –defined, high-mifepristone plasma level and markers of GR antagonism (increases in ACTH and cortisol) with treatment.

Source: Biological Psychiatry - January 17, 2018 Category: Psychiatry Authors: Thaddeus Block, Harvey Kushner, Ned Kalin, Craig Nelson, Joseph Belanoff, Alan Schatzberg Tags: Archival Report Source Type: research